Floating Button
Home News Contracts

Hyphens Pharma subsidiary enters into exclusive licensing agreement with Maruho for shingles medication

Felicia Tan
Felicia Tan • 2 min read
Hyphens Pharma subsidiary enters into exclusive licensing agreement with Maruho for shingles medication
The agreement will not have a material effect on Hyphens Pharma’s net tangible assets (NTA) or earnings per share (EPS) for the group’s FY2024 ending Dec 31. Photo: Albert Chua/The Edge Singapore
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Hyphens Pharma International’s subsidiary, Hyphens Pharma, has entered into an exclusive license, development and commercialisation agreement with Maruho. The agreement is for the exclusive rights to register and commercialise Amenalief Tab 200mg tablets in the 10 Asean countries.

The medication is for the treatment of herpes zoster, which is also known as shingles. It can also treat recurrent herpes simplex.

Shingles is caused by a reactivation of the dormant chickenpox varicella-zoster virus. In Singapore, over 90% adults aged over 50 years old carry the viral infection. Older people are also said to be at higher risk of developing shingles. Anti-viral medications like Amenalief are the main treatment for shingles, says Hyphens Pharma.

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2026 The Edge Publishing Pte Ltd. All rights reserved.